Blue Owl Capital Holdings (CNTX) Discloses 5.54% Ownership in Context Therapeutics

Rhea-AI Filing Summary

Context Therapeutics Inc. ownership update: Blue Owl Capital Holdings LP reports beneficial ownership of 5,089,015 shares of Common Stock, representing 5.54% of the class based on 91,879,177 shares outstanding as of May 4, 2026, per the issuer's 10-Q.

The filing is an amendment to a Schedule 13G/A and is signed by the Reporting Person's Chief Compliance Officer.

Insights

Institutional Ownership Analyst

Blue Owl reports a 5.54% passive stake in Context Therapeutics.

Blue Owl Capital Holdings LP discloses beneficial ownership of 5,089,015 shares representing 5.54% based on May 4, 2026 outstanding share count. The statement is filed as a Schedule 13G/A amendment and signed by a compliance officer.

The filing cites Rule 13d-4 and contains a standard non-admission clause about beneficial ownership. Subsequent filings may show changes; timing and intent are not specified in the provided excerpt.

Key Figures

Shares beneficially owned: 5,089,015 shares Percent of class: 5.54% Shares outstanding (source): 91,879,177 shares +2 more

5 metrics

Shares beneficially owned 5,089,015 shares Beneficial ownership reported by Blue Owl Capital Holdings LP

Percent of class 5.54% Calculated using 91,879,177 shares outstanding as of May 4, 2026

Shares outstanding (source) 91,879,177 shares As reported in the Issuer's 10-Q referenced in this filing (as of May 4, 2026)

CUSIP 21077P108 Context Therapeutics Inc. Common Stock CUSIP

Signature date 05/13/2026 Date the amendment was signed by the Chief Compliance Officer

Key Terms

Schedule 13G/A, beneficial ownership, Rule 13d-4

3 terms

Schedule 13G/A regulatory

"Amendment No. 2 ) Context Therapeutics Inc."

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficial ownership financial

"Amount beneficially owned: See response to row 9 on the cover page."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Rule 13d-4 regulatory

"Pursuant to Rule 13d-4 of the Act, the Reporting Person declares"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/14/2026 - 04:20 PM Learn about SEC filing dates

FAQ

What stake does Blue Owl hold in Context Therapeutics (CNTX)?

Blue Owl reports 5,089,015 shares, equal to 5.54% of Common Stock. This percentage uses 91,879,177 shares outstanding as of May 4, 2026, per the issuer's 10-Q referenced in the filing.

When is the outstanding share count used to calculate Blue Owl's percentage?

The filing cites an outstanding share count of 91,879,177 shares as of May 4, 2026. That figure is drawn from the issuer's 10-Q referenced in the Schedule 13G/A amendment signed on May 13, 2026.

Does the Schedule 13G/A indicate Blue Owl has voting or dispositive control?

The cover page shows Blue Owl has sole voting power of 5,089,015 and sole dispositive power of 5,089,015. The filing also includes a Rule 13d-4 clause stating the Reporting Person does not admit beneficial ownership for Sections 13(d)/(g) purposes.

Who signed the Schedule 13G/A amendment for Blue Owl?

The amendment is signed by Karen Hager, identified as Chief Compliance Officer, with a signature date of 05/13/2026. The filing lists Blue Owl Capital Holdings LP as the Reporting Person and provides its New York address.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Context Therapeutics Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

21077P108

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 21077P108

1

Names of Reporting Persons

Blue Owl Capital Holdings LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,089,015.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,089,015.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,089,015.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.54 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The reported percentage is calculated based on 91,879,177 shares of Common Stock outstanding as of May 4, 2026, as reported on the Issuer's 10-Q filed with the Securities and Exchange Commission on May 6, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Context Therapeutics Inc.
(b)	Address of issuer's principal executive offices: 2001 Market Street, Suite 3915, Unit #15, Philadelphia, PA 19103
Item 2.
(a)	Name of person filing: This statement is filed by Blue Owl Capital Holdings LP, referred to herein as the "Reporting Person."
(b)	Address or principal business office or, if none, residence: 399 Park Avenue, New York, New York 10022
(c)	Citizenship: See response to row 4 on the cover page.
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 21077P108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See response to row 9 on the cover page. Pursuant to Rule 13d-4 of the Act, the Reporting Person declares that filing this statement shall not be deemed an admission that the Reporting Person is a beneficial owner of the reported securities, for purposes of Section 13(d) and/or Section 13(g) or for any other purpose.
(b)	Percent of class: See response to row 11 on the cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to row 5 on the cover page.
	(ii) Shared power to vote or to direct the vote: See response to row 6 on the cover page.
	(iii) Sole power to dispose or to direct the disposition of: See response to row 7 on the cover page.
	(iv) Shared power to dispose or to direct the disposition of: See response to row 8 on the cover page.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Blue Owl Capital Holdings LP

Signature:	/s/ Karen Hager
Name/Title:	Karen Hager / Chief Compliance Officer
Date:	05/13/2026